Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Cardiovascular Risk Reports

• Publication date

  2015-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12170-015-0449-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

  2015cited by this paper
• Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study.

  2015cited by this paper
• Time-related increase in urinary testosterone levels and stable semen analysis parameters after bariatric surgery in men.

  2015cited by this paper
• Effects of sulfonylurea as initial treatment on testosterone of middle-aged men with type 2 diabetes: A 16-week, pilot study

  2015cited by this paper
• Adverse effects of androgen deprivation therapy and strategies to mitigate them.

  2015cited by this paper
• Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta‐analysis of randomized controlled clinical trials

  2015cited by this paper
• Re: Testosterone Products: Drug Safety Communication - FDA Cautions about Using Testosterone Products for Low Testosterone due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke.

  2015cited by this paper
• Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Testosterone, cardiovascular disease, and mortality in men: living in the dark

  2014cited by this paper
• Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial

  2014cited by this paper
• Andrology: Testosterone and cardiovascular risk—deciphering the statistics

  2014cited by this paper
• Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.

  2014cited by this paper
• The association of androgens with QT interval and heart rate in US men.

  2014cited by this paper
• Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men

  2014cited by this paper
• Avoiding blunders involving 'immortal time'.

  2014cited by this paper
• Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study.

  2014cited by this paper
• Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.

  2014cited by this paper
• Why do statins reduce cardiovascular disease more than other lipid modulating therapies?

  2014cited by this paper
• Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis

  2014cited by this paper
• Potential role of skeletal muscle glucose metabolism on the regulation of insulin secretion

  2014cited by this paper
• Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.

  2014cited by this paper
• Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.

  2014cited by this paper
• Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

  2014cited by this paper
• Genetic insights into cardiometabolic risk factors.

  2014cited by this paper
• Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients.

  2014cited by this paper
• Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Deaths and cardiovascular events in men receiving testosterone.

  2014cited by this paper
• Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials

  2013cited by this paper
• Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials

  2013cited by this paper
• Circulating free testosterone in obese men after bariatric surgery increases in parallel with insulin sensitivity

  2013cited by this paper
• Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies.

  2013cited by this paper
• Promoting "low T": a medical writer's perspective.

  2013influential reference
• Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

  2013cited by this paper
• Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.

  2013cited by this paper
• Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies.

  2013cited by this paper
• Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse

  2013cited by this paper
• Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000–2010

  2013cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Clinical review: Klinefelter syndrome--a clinical update.

  2013cited by this paper
• Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.

  2013cited by this paper
• Words of wisdom. Re: Gonadal steroids and body composition, strength, and sexual function in men.

  2013cited by this paper
• Cardiovascular events and intensity of treatment in polycythemia vera.

  2013cited by this paper
• Caloric Restriction Increases Serum Testosterone Concentrations in Obese Male Subjects by Two Distinct Mechanisms

  2013cited by this paper
• Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials.

  2013cited by this paper
• Glucose-6-phosphate dehydrogenase deficiency: disadvantages and possible benefits.

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

  2013cited by this paper
• Testosterone treatment and mortality in men with low testosterone levels.

  2012cited by this paper
• The influence of sex and gender on the immune response.

  2012cited by this paper
• Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

  2012cited by this paper
• The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial

  2012cited by this paper
• A Mendelian Randomization Study

  2012cited by this paper
• Metformin and the Risk of Cancer

  2012cited by this paper
• Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

  2012cited by this paper
• Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials

  2012cited by this paper
• Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)

  2011cited by this paper
• Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2011cited by this paper
• Type 2 diabetes as an inflammatory disease

  2011cited by this paper
• Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis.

  2011cited by this paper
• Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

  2011cited by this paper
• Resistance Training in the Treatment of the Metabolic Syndrome

  2010cited by this paper
• Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus.

  2010cited by this paper
• Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis

  2010cited by this paper
• Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.

  2010cited by this paper
• Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial.

  2010cited by this paper
• Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

  2010cited by this paper
• The association of serum testosterone levels and ventricular repolarization

  2009cited by this paper
• Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone.

  2009cited by this paper
• Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze‐Bagno A Ripoli study

  2008cited by this paper
• Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes

  2008cited by this paper
• Effects of Oral Testosterone Treatment on Myocardial Perfusion and Vascular Function in Men With Low Plasma Testosterone and Coronary Heart Disease

  2008cited by this paper
• Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.

  2006cited by this paper
• Glycated hemoglobin as a marker of cardiovascular risk

  2006cited by this paper
• Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.

  2006cited by this paper
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

  2005cited by this paper
• Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Mortality in patients with Klinefelter syndrome in Britain: a cohort study.

  2005cited by this paper
• Castration reduces platelet thromboxane A2 receptor density and aggregability.

  2005cited by this paper
• Testosterone and aging : clinical research directions

  2004cited by this paper
• Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency

  2003cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Myocardial infarction and thalassemia trait: An example of heterozygote advantage

  1995cited by this paper
• Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.

  1995cited by this paper
• QTc Prolongation Measured by Standard 12‐Lead Electrocardiography Is an Independent Risk Factor for Sudden Death Due to Cardiac Arrest

  1991cited by this paper
• Heart rate and cardiovascular mortality: the Framingham Study.

  1987cited by this paper
• The hematocrit in patients with myocardial infarction.

  1962cited by this paper
• Online Appendices

  year unknowncited by this paper

• No citing papers are available for this paper.